ACKNOWLEDGEMENTS
This study was supported by Grants-in Aid from the Research Committee of CNS Degenerative Diseases; Research on Policy Planning and Evaluation for Rare and Intractable Diseases; Health, Labour and Welfare Sciences Research Grants; and the Ministry of Health, Labour and Welfare, Japan (20FC1049), and grants from the Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research (C) (#21K12711). The funders had no role in the study design, data collection or analysis, decision to publish, or manuscript preparation. The Department of Neurodegenerative and Demented Disorders was supported by grants from GLORY Ltd., Kirin Company Ltd., Mitsubishi UFJ Lease & Finance Company Ltd.
AUTHOR CONTRIBUTIONS
Study conception and design: G.O., T.K., S.O., T.H., N.H.; Data collection and study execution: G.O., M.O., M.M., R.W., ; Interpretation of the data: G.O., M.O., K.M., H. U., X.L., T. K., R. W., S. O., T.H., N.H.; Analysis: G.O., M.O., K.M., H. U., X.L., T. K., R. W.; the first draft of the manuscript was written by G.O., H. U, and all authors commented on subsequent versions of the manuscript. All authors read and approved the final manuscript.
COMPETING INTERESTS
G.O. has received grants from Grant-in-Aid for Scientific Research (Kakenhi) and Novartis Pharma K.K. and honoraria from AbbVie Inc., Boston Scientific Corporation, Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Medtronic Japan Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co. Ltd., and Takeda Pharmaceutical Company Limited.
T.H. has received grants from: the Japan Agency for Medical Research and Development (grant numbers: 20dm0107156, 21wm0425015, 21ak0101112, and 21dk0207055), the Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research (grant number: 21K07424), the Setsuro Fujii Memorial Osaka Foundation for Promotion of Fundamental Medical Research, and Daiichi Sankyo TaNeDS; and research funds from: Daiichi Sankyo TaNeDS Funding Program. He has received speaker’s honoraria from: Sumitomo Dainippon Pharma Co. Ltd., Takeda Pharmaceutical Company Limited, FP Pharmaceutical Corporation, Kyowa Kirin Co., Ltd., Nihon Medi-Physics Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd, and Otsuka Pharmaceutical Co., Ltd.
N.H. has received consulting fees from GlaxoSmithKline K.K., AbbVie Inc., Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co. Ltd., Kyowa Kirin Co., Ltd., Hisamitsu Pharmaceutical Co., Inc., Meiji Seika Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd, and FP Pharmaceutical Corporation; lecture fees from MSD K.K., Eli Lilly Japan K.K., Eisai Co., Ltd., FP Pharmaceutical Corporation, Otsuka Pharmaceutical Co., Ltd., Tsumura & Co., Kyowa Kirin Co., Ltd., GlaxoSmithKline K.K., Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, Nihon Medi-Physics Co., Ltd., Novartis Pharma K.K., Pfizer Japan Inc., Nippon Boehringer Ingelheim Co., Ltd., Sumitomo Dainippon Pharma Co. Ltd., and Daiichi Sankyo Company, Limited; honoraria from FP Pharmaceutical Corporation, Novartis Pharma K.K., Kyowa Kirin Co., Ltd., and AbbVie Inc.; research support from Otsuka Pharmaceutical Co., Ltd.; and grants from Astellas Pharma Inc., Eisai Co., Ltd., GlaxoSmithKline K.K., Sumitomo Dainippon Pharma Co. Ltd., Takeda Pharmaceutical Company Limited, Novartis Pharma K.K., Pfizer Japan Inc., Kyowa Kirin Co., Ltd., Medtronic Japan Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Boston Scientific Corporation, Kissei Pharmaceutical Co., Ltd, and Otsuka Pharmaceutical Co., Ltd.
M.O. is an employee of Department of Neurodegenerative and Demented Disorders, Juntendo University Graduate School of Medicine, Tokyo, Japan.
K. M. is an employee of GLORY Ltd., Tokyo, Japan.
H.U., X.L.,K.T.,R.W.,S.O are employees of IBM Consulting Tokyo, Japan
DATA AVAILABILITY
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.